Search

Haleon PLC

Cerrado

Sector Salud

394.4 0.48

Resumen

Variación precio

24h

Actual

Mínimo

392.7

Máximo

397.2

Métricas clave

By Trading Economics

Ingresos

58M

423M

Ventas

-144M

2.8B

P/B

Media del Sector

29.48

103.001

BPA

0.033

Rentabilidad por dividendo

1.275

Margen de beneficio

14.491

EBITDA

-2M

687M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

-2.59 downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.27%

7.76%

Fecha Próximo Dividendo

19 sept 2024

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

59M

35B

Apertura anterior

393.92

Cierre anterior

394.4

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

97 / 365 Clasificación en Healthcare

Haleon PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 ago 2024, 06:54 UTC

Ganancias

Haleon Lifts Profit Guidance on Profit Rise

26 jun 2024, 13:33 UTC

Adquisiciones, fusiones, absorciones

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26 jun 2024, 12:32 UTC

Adquisiciones, fusiones, absorciones

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

17 may 2024, 06:24 UTC

Adquisiciones, fusiones, absorciones

GSK Sells Last Haleon Shares for $1.58 Billion

16 may 2024, 16:46 UTC

Adquisiciones, fusiones, absorciones

GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update

16 may 2024, 16:28 UTC

Adquisiciones, fusiones, absorciones

GSK to Sell Stake in Haleon Valued at About $1.61 Billion

1 ago 2024, 13:08 UTC

Charlas de Mercado
Ganancias

Haleon 1H Results Are Positive -- Market Talk

1 ago 2024, 07:08 UTC

Charlas de Mercado
Ganancias

Haleon's 1H Results Don't Surprise -- Market Talk

1 ago 2024, 06:09 UTC

Ganancias

Haleon Launches BuyBack Program Up to GBP185M

1 ago 2024, 06:05 UTC

Ganancias

Haleon Now Expects 2024 Operating Profit Growth to Grow High-Single Digit

1 ago 2024, 06:04 UTC

Ganancias

Haleon Had Seen Organic Revenue Growth of 4% to 6%

1 ago 2024, 06:04 UTC

Ganancias

Haleon Backs 2024 Organic Revenue Growth View

1 ago 2024, 06:03 UTC

Ganancias

Haleon Declares Interim Dividend of 2.0p per share

1 ago 2024, 06:02 UTC

Ganancias

Haleon 1H Adj EBIT Consensus GBP1.275B

1 ago 2024, 06:02 UTC

Ganancias

Haleon 1H Adj Oper Pft GBP1.29B

1 ago 2024, 06:01 UTC

Ganancias

Haleon 1H Organic Rev Growth Consensus 3.5%

1 ago 2024, 06:01 UTC

Ganancias

Haleon 1H Organic Rev Growth 3.5%

1 ago 2024, 06:01 UTC

Ganancias

Haleon 1H Revenue Consensus GBP5.69B

1 ago 2024, 06:01 UTC

Ganancias

Haleon 1H Rev GBP5.69B

26 jun 2024, 11:54 UTC

Adquisiciones, fusiones, absorciones

Haleon: All Other 2024 Guidance Unchanged

26 jun 2024, 11:54 UTC

Adquisiciones, fusiones, absorciones

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26 jun 2024, 11:52 UTC

Adquisiciones, fusiones, absorciones

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26 jun 2024, 11:51 UTC

Adquisiciones, fusiones, absorciones

Haleon: Deal Expected to Complete Early 4Q

26 jun 2024, 11:50 UTC

Adquisiciones, fusiones, absorciones

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26 jun 2024, 11:49 UTC

Adquisiciones, fusiones, absorciones

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26 jun 2024, 11:48 UTC

Adquisiciones, fusiones, absorciones

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26 jun 2024, 11:47 UTC

Adquisiciones, fusiones, absorciones

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26 jun 2024, 11:46 UTC

Adquisiciones, fusiones, absorciones

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

17 may 2024, 06:09 UTC

Adquisiciones, fusiones, absorciones

GSK Sells Last Haleon Shares for $1.58 Bln

16 may 2024, 15:46 UTC

Adquisiciones, fusiones, absorciones

GSK PLC: Shares Are Equivalent to Around 4.2% of Haleon's Share Capital

Haleon PLC Esperado

Precio Objetivo

By TipRanks

-2.59% caída

Estimación a 12 meses

Media 382.9 GBX  -2.59%

Máximo 450 GBX

Mínimo 300 GBX

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Haleon PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

5

Comprar

4

Mantener

1

Vender

Sentimiento

By Acuity

97 / 365 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

$

Acerca de Haleon PLC

Haleon plc is a consumer healthcare company. The Company’s product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.